Balancing Method for Pain Related to Advanced Cancer
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04176575 |
Recruitment Status :
Recruiting
First Posted : November 25, 2019
Last Update Posted : July 6, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain, Cancer Metastatic Cancer Invasive Cancer | Other: Acupuncture | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Estimated Enrollment : | 60 participants |
Allocation: | N/A |
Intervention Model: | Single Group Assignment |
Intervention Model Description: | This clinical trial is a descriptive, interventional, and open-label pilot study. |
Masking: | None (Open Label) |
Primary Purpose: | Supportive Care |
Official Title: | Acupuncture for Pain Related to Advanced Cancer Using Dr. Tan's Balancing Method |
Actual Study Start Date : | July 5, 2022 |
Estimated Primary Completion Date : | October 5, 2023 |
Estimated Study Completion Date : | October 5, 2023 |
Arm | Intervention/treatment |
---|---|
Experimental: Acupuncture
Eligible participants:
|
Other: Acupuncture
Acupuncture involves inserting thin needles into precise points on the body, known as acupuncture points, for therapeutic effect. Acupuncture will be provided by a licensed acupuncturist utilizing Dr. Tan's Balancing Method. |
- Measuring effectiveness of acupuncture by assessing change in pain ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Numeric Rating Scale v.1.0 - Pain Intensity 1a (NRS) [ Time Frame: Baseline, each visit; up to 18 weeks (per participant) ]Participant report of pain on average on a scale from 'no pain' (0) to "worst imaginable pain" (10). Higher scores mean worse outcome.
- Measuring effectiveness of acupuncture by assessing change in pain intensity ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Item Bank v.1.0 measures: Pain Intensity Scale [ Time Frame: Baseline, each week, at follow-up; up to 18 weeks (per participant) ]Participant report of symptoms in the past week on a scale from "no pain" (1) to "very severe" (5). Higher scores mean worse outcome. These measures assess changes in symptoms over the course of study participation.
- Measuring effectiveness of acupuncture by assessing change in pain interference ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Item Bank v.1.0 measures: Pain Interference Short Form 4a [ Time Frame: Baseline, each week, at follow-up; up to 18 weeks (per participant) ]Participant report of symptoms in the past week on a scale from "not at all" (1) to "very much" (5). Higher scores mean worse outcome. These measures assess changes in symptoms over the course of study participation.
- Measuring effectiveness of acupuncture by assessing change in fatigue ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Item Bank v.1.0 measures: Fatigue Short Form 4a [ Time Frame: Baseline, each week, at follow-up; up to 18 weeks (per participant) ]Participant report of symptoms in the past week on a scale from "not at all" (1) to "very much" (5). Higher scores mean worse outcome. These measures assess changes in symptoms over the course of study participation.
- Measuring effectiveness of acupuncture by assessing change in anxiety symptom ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Item Bank v.1.0 measures: Emotional Distress-Anxiety - Short Form 4a [ Time Frame: Baseline, each week, at follow-up; up to 18 weeks (per participant) ]Participant report of symptoms in the past week on a scale from "never" (1) to "always" (5). Higher scores mean worse outcome. These measures assess changes in symptoms over the course of study participation.
- Measuring effectiveness of acupuncture by assessing change in sleep disturbance ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Item Bank v.1.0 measures: Sleep Disturbance - Short Form 4a [ Time Frame: Baseline, each week, at follow-up; up to 18 weeks (per participant) ]Participant report of symptoms in the past week on a scale from "very poor/very much" (1) to "very good/not at all" (5). Higher scores mean worse outcome. These measures assess changes in symptoms over the course of study participation.
- Measuring effectiveness of acupuncture by assessing change in gastrointestinal symptom ratings Weekly from Week 1-Week 12 and 4 week follow-up using PROMIS ® Item Bank v.1.0 measures: Gastrointestinal Nausea and Vomiting [ Time Frame: Baseline, each week, at follow-up; up to 18 weeks (per participant) ]Participant report of symptoms in the past week on a scale from "never" (1) to "always" (5). Higher scores mean worse outcome. These measures assess changes in symptoms over the course of study participation.
- Measuring effectiveness of acupuncture by assessing improvement in global symptoms ratings at Week 4 and Weeks 9-12 and 4 week follow-up using Patient Global Index of Change: Improvement (PGIC-I) [ Time Frame: Week 5, Weeks 9-12 and follow-up; up to 18 weeks (per participant) ]Participant rating of symptom severity on a scale of -2 (much better) to 2 (much worse). Higher scores mean worse outcome. This measure assesses changes in symptoms over the course of study participation.
- Measuring health intervention attitudes and beliefs at start of study by using Healing Encounters Attitudes List Measures: Treatment Expectancy (HEAL-TEX) [ Time Frame: Baseline Visit ]Participant report of treatment expectancy on a 5 point scale (1-5) ranging from "Not at all" (1) to "Very much" (5). Higher scores ("Very much") indicate higher treatment expectancy.
- Measuring perception of effectiveness based on patient-provider connections by using Healing Encounters Attitudes List: Perception of the Patient-Provider Connection (HEAL-PPC) [ Time Frame: Week 4 and Weeks 9, 10, 11, 12 ]Participant report of the patient-provider connection on a 5 point scale ranging from "Not at all" to "Very much". Higher scores ("Very much") mean better outcome. This measure assesses a change in the patient-provider connection from the beginning of study participation to the end.
- Measuring spiritual attitudes and beliefs at start of study by using Healing Encounters Attitudes List Measures: Spirituality (HEAL-SPT) [ Time Frame: Baseline Visit ]Participant report of Spirituality on a 5 point scale (1-5) ranging from "Not at all" (1) to "Very much" (5). Higher scores ("Very much") indicate higher personal spiritual belief.
- Monitoring and recording use of opioids throughout the study protocol using Opioid Use Questionnaire [ Time Frame: Baseline; weekly; follow-up; up to 18 weeks (per participant) ]Internally-developed, participant report of pain medication use. This questionnaire collects dosing/frequency information, which is used to calculate morphine equivalent dosing (MED). This information will be used to assess change in pain medication use over the course of study participation.
- Assessing for treatment-related adverse events as recorded by Acupuncture Safety Record [ Time Frame: Baseline; each visit and follow-up; up to 18 weeks (per participant) ]Internally-developed, participant report of acupuncture related adverse events. Administered in a checklist form. More selections on this form means more acupuncture related adverse events.
- Assessing for treatment-related and illness-related symptoms as recorded by Symptoms Checklist (SC) [ Time Frame: Baseline; each visit and follow-up; up to 18 weeks (per participant) ]Captures new or worsening health problems participants have experienced since their last study visit. More selections on this form means worse outcome.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Age 18 or older.
- Current diagnosis of a malignancy.
- Locally invasive, metastatic, or systemic involvement from the disease, which would be anticipated to produce pain.
- Average pain level, on a numeric rating scale, of 4/10 or higher on the Numeric Rating Scale (NRS).
- Receiving treatment through Hillman Cancer Center, Magee Hospital, or 1 of the University of Pittsburgh Cancer Institute sites.
- Able to read and write English.
Exclusion Criteria:
- Experience with acupuncture within the prior 3 months.
- Platelet count < 50,000.
- Absolute Neutrophil Count < 1,000.
- Treatment with anticoagulant medication, other than prophylactic levels of heparin or low molecular weight heparin preparations or anti-platelet agents.
- Known coagulopathy.
- Pregnancy. While it is unlikely that any patients undergoing advanced cancer treatment will be pregnant, given the lack of documented safety, this is an exclusion.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04176575
Contact: Leah C Northrop, MS | 4126236872 | northroplc@upmc.edu | |
Contact: Ronald M Glick, MD | 4126236872 | glickrm@upmc.edu |
United States, Pennsylvania | |
UPMC Center for Integrative Medicine | Recruiting |
Pittsburgh, Pennsylvania, United States, 15218 | |
Contact: Leah C Northrop, MS 412-623-6872 northroplc@upmc.edu | |
Contact: Brittany Kail, BSBA 412-623-1203 kailb@upmc.edu | |
Principal Investigator: Ronald Glick |
Principal Investigator: | Ronald M Glick, MD | Hillman Cancer Center |
Responsible Party: | Ronald M. Glick, MD, Associate Professor, University of Pittsburgh |
ClinicalTrials.gov Identifier: | NCT04176575 |
Other Study ID Numbers: |
HCC 21-182 |
First Posted: | November 25, 2019 Key Record Dates |
Last Update Posted: | July 6, 2022 |
Last Verified: | July 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
Acupuncture Cancer Pain |
Cancer Pain Pain Neurologic Manifestations |